English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Personalized medicine is the concept of tailoring pharmacotherapy to an individual patient based on their predicted response to that therapy [1, 2]. Its application to perioperative medicine is novel and has much potential for growth. Pharmacogenomics (PGx) is the study of inherited differences in drug metabolism. It is a key component of personalized medicine as a better understanding of the association of an individual’s genome and response to therapy may potentially improve outcomes [1, 2]. Over the last decade, several studies have demonstrated an association of genotype with efficacy of various medications applicable to the surgical setting [3–8]. Furthermore, in one recent study when PGx results were integrated into an Enhanced Recovery After Surgery (ERAS) pathway for abdominal surgery, there was an improvement in analgesia and decrease in opioid consumption [9]. Although perioperative PGx testing holds much promise, we have not yet been able to achieve successful implementation across our medical systems and into daily practice. In order to obtain more widespread adoption of perioperative personalized medicine, there needs to be: 1) more substantial evidence that perioperative outcomes improve with PGx; 2) easy-to-access and -understand information technology interfaces that display the relevant PGx information for a patient; and 3) systems put into place that allow PGx to easily fit into regular clinical workflow. The first point requires the healthcare researcher community to utilize PGx to create the evidence based from highquality prospective studies. The second and third points will require adequate institutional informatics support and infrastructure. Several genes have already been implicated in perioperative medication metabolism [1]. Analysis and presentation of the results of individual mutations to these genes can theoretically be long and daunting. One option is to present a list of common perioperative medications that have some prevalence of genetic risk and classify each medication based on the estimated degree of metabolism that patient has for it (i.e. ultra-metabolizer, extensive metabolizer, slow metabolizer, etc) (Fig. 1). Finally, to facilitate clinical adoption, PGx screening results should be transferred directly into electronic health record (EHR) systems and seamlessly integrated into the patients’ anesthesia and postoperative record. Important components of a successfully integrated PGx program into an EHR include: 1) customized report generation unique to each health institution; 2) tailored data analytics; 3) data presentable for research studies; 4) easy-to-use provider-facing interface in the EHR explaining the key salient results (and recommendations) for a patient as well as a separate section with more granular detail; and 5) EHR-integrated real-time alerts warning providers regarding genetic risk to medications. Ideally, the workflow of PGx screening should start in the surgeon’s office or preoperative evaluation clinic, prior to the scheduled surgery. This will allow adequate time for results to become available on the day of the surgery. Upon reviewing the patient’s EHR on the day of surgery, the healthcare providers could be alerted to potential genetic risks to specific This article is part of the Topical Collection on Patient Facing Systems

Preoperative Genetic Testing and Personalized Medicine: Changing the Care Paradigm